BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 30168587)

  • 1. An adjuvant compound that enhances immunogenicity at fractional doses of the Sabin-inactivated poliovirus vaccine (sIPV) with a long duration of protection in a rat model.
    Song S; Liu Z; Zhou J; Cai W; Yang H; Ma L; Gao J; Li W; Liao G
    J Med Virol; 2019 Jan; 91(1):14-21. PubMed ID: 30168587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analyzed immunogenicity of fractional doses of Sabin-inactivated poliovirus vaccine (sIPV) with intradermal delivery in rats.
    Ma L; Cai W; Sun M; Cun Y; Zhou J; Liu J; Hu W; Zhang X; Song S; Jiang S; Liao G
    Hum Vaccin Immunother; 2016 Dec; 12(12):3125-3131. PubMed ID: 27558963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the dose-sparing effect of adjuvanted Sabin-inactivated poliovirus vaccine (sIPV).
    Li Z; Ding W; Guo Q; Liu Z; Zhu Z; Song S; Li W; Liao G
    Hum Vaccin Immunother; 2018; 14(8):1987-1994. PubMed ID: 29601259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal and sublingual delivery of inactivated polio vaccine.
    Kraan H; Soema P; Amorij JP; Kersten G
    Vaccine; 2017 May; 35(20):2647-2653. PubMed ID: 28400164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model.
    Bockstal V; Tiemessen MM; Achterberg R; Van Wordragen C; Knaapen AM; Serroyen J; Marissen WE; Schuitemaker H; Zahn R
    Vaccine; 2018 Nov; 36(46):6979-6987. PubMed ID: 30314910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants.
    Verdijk P; Rots NY; van Oijen MG; Weldon WC; Oberste MS; Okayasu H; Sutter RW; Bakker WA
    Vaccine; 2014 Sep; 32(39):4938-44. PubMed ID: 25043278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparing the immunogenicity and safety of sequential inoculation of sIPV followed by bOPV (Ⅰ+Ⅲ) in different dosage forms].
    Ye H; Huang T; Ying ZF; Li GL; Che YC; Zhao ZM; Wang JF; Yang XL; Shi L; Jiang RJ; Liu XC; Mo ZJ; Li CG; Yang JS
    Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Jan; 52(1):43-49. PubMed ID: 29334707
    [No Abstract]   [Full Text] [Related]  

  • 8. [Immunogenicity of sabin inactivated poliovirus vaccine induced by diphtheria-tetanus-acellular pertussis and Sabin inactivated poliovirus combined vaccine].
    Ma Y; Qin M; Hu HQ; Ji G; Feng L; Gao N; Gu J; Xie BF; He JH; Sun MB
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Jun; 25(3):197-200. PubMed ID: 21977591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains.
    Westdijk J; Koedam P; Barro M; Steil BP; Collin N; Vedvick TS; Bakker WA; van der Ley P; Kersten G
    Vaccine; 2013 Feb; 31(9):1298-304. PubMed ID: 23313617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults.
    Verdijk P; Rots NY; van Oijen MG; Oberste MS; Boog CJ; Okayasu H; Sutter RW; Bakker WA
    Vaccine; 2013 Nov; 31(47):5531-6. PubMed ID: 24063976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of experimental stand-alone trivalent, inactivated Sabin-strain polio vaccine formulations in healthy infants: A randomized, observer-blind, controlled phase 1/2 trial.
    Cramer JP; Jimeno J; Han HH; Lin S; Hartmann K; Borkowski A; Sáez-Llorens X
    Vaccine; 2020 Jul; 38(33):5313-5323. PubMed ID: 32563609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial.
    Mulligan MJ; Bernstein DI; Winokur P; Rupp R; Anderson E; Rouphael N; Dickey M; Stapleton JT; Edupuganti S; Spearman P; Ince D; Noah DL; Hill H; Bellamy AR;
    JAMA; 2014 Oct; 312(14):1409-19. PubMed ID: 25291577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactogenicity and immunogenicity of inactivated poliovirus vaccine produced from Sabin strains: a phase I Trial in healthy adults in Cuba.
    Resik S; Tejeda A; Fonseca M; Alemañi N; Diaz M; Martinez Y; Garcia G; Okayasu H; Burton A; Bakker WA; Verdijk P; Sutter RW
    Vaccine; 2014 Sep; 32(42):5399-404. PubMed ID: 25131734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and Safety of a Sabin Strain-Based Inactivated Polio Vaccine: A Phase 3 Clinical Trial.
    Hu Y; Wang J; Zeng G; Chu K; Jiang D; Zhu F; Ying Z; Chen L; Li C; Zhu F; Yin W
    J Infect Dis; 2019 Oct; 220(10):1551-1557. PubMed ID: 30958543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of fractional-dose of inactivated poliomyelitis vaccine made from Sabin strains delivered by intradermal vaccination in Wistar rats.
    Ma Y; Ying Z; Li J; Gu Q; Wang X; Cai L; Shi L; Sun M
    Biologicals; 2022 Jan; 75():3-11. PubMed ID: 35058137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Enhancing the immunogenicity of inactivated polio vaccines with chitosan used as an adjuvant].
    Gendon IuZ; Markushin SG; Akopova II; Krivtsov GG; Akhmatova NK; Koptiaeva IB; Vasil'ev IuM
    Vopr Virusol; 2011; 56(6):28-32. PubMed ID: 22359946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Thermostable Lyophilized Sabin Inactivated Poliovirus Vaccine.
    Shin WJ; Hara D; Gbormittah F; Chang H; Chang BS; Jung JU
    mBio; 2018 Nov; 9(6):. PubMed ID: 30482835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of Two Different Sequential Schedules of Inactivated Polio Vaccine Followed by Oral Polio Vaccine Versus Oral Polio Vaccine Alone in Healthy Infants in China.
    Li RC; Li CG; Wang HB; Luo HM; Li YP; Wang JF; Ying ZF; Yu WZ; Shu JD; Wen N; Vidor E
    J Pediatric Infect Dis Soc; 2016 Sep; 5(3):287-96. PubMed ID: 26407255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The effect of aluminum adjuvant and immunization schedule on immunogenicity of Sabin inactivated poliovirus vaccine].
    Wang F; Zhang M; Xie BF; Cao H; Tong SY; Wang JR; Yu XP; Tang Y; Yang JR; Sun MB
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2013 Apr; 27(2):102-4. PubMed ID: 24044212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, dose-finding trial.
    Chu K; Ying Z; Wang L; Hu Y; Xia J; Chen L; Wang J; Li C; Zhang Q; Gao Q; Hu Y
    Vaccine; 2018 Oct; 36(45):6782-6789. PubMed ID: 30249424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.